SRC and melanoma: It has been demonstrated that luteolin exerts antimelanoma effects in vitro and in vivo without overt toxicity to normal cells and also in melanoma-bearing mice through the suppression of STAT3 signaling via binding to SRC protein (Li et al., 2022).